Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free GNTA Stock Alerts

Genenta Science (GNTA) Competitors

Genenta Science logo
$0.59 -0.03 (-4.27%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$0.60 +0.02 (+2.59%)
As of 05/13/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

GNTA vs. IZTC, PYRGF, GRML, IBIO, and HYFT

Should you buy Genenta Science stock or one of its competitors? MarketBeat compares Genenta Science with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genenta Science include Invizyne Technologies (IZTC), PyroGenesis Canada (PYRGF), Greenland Mines Ltd. Common Stock (GRML), iBio (IBIO), and MindWalk (HYFT). These companies are all part of the "pharmaceutical products" industry.

How does Genenta Science compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Company Net Margins Return on Equity Return on Assets
Invizyne TechnologiesN/A N/A N/A
Genenta Science N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invizyne TechnologiesN/AN/AN/AN/AN/A
Genenta ScienceN/AN/A-$7.39MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invizyne Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Genenta Science had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 2 mentions for Genenta Science and 0 mentions for Invizyne Technologies. Genenta Science's average media sentiment score of 1.44 beat Invizyne Technologies' score of 0.00 indicating that Genenta Science is being referred to more favorably in the news media.

Company Overall Sentiment
Invizyne Technologies Neutral
Genenta Science Positive

15.1% of Genenta Science shares are held by institutional investors. 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Genenta Science beats Invizyne Technologies on 5 of the 5 factors compared between the two stocks.

How does Genenta Science compare to PyroGenesis Canada?

PyroGenesis Canada (NASDAQ:PYRGF) and Genenta Science (NASDAQ:GNTA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

0.0% of PyroGenesis Canada shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 47.7% of PyroGenesis Canada shares are held by company insiders. Comparatively, 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

PyroGenesis Canada has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

In the previous week, PyroGenesis Canada and PyroGenesis Canada both had 2 articles in the media. Genenta Science's average media sentiment score of 1.44 beat PyroGenesis Canada's score of 0.00 indicating that Genenta Science is being referred to more favorably in the news media.

Company Overall Sentiment
PyroGenesis Canada Neutral
Genenta Science Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PyroGenesis Canada
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Genenta Science has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%.

Company Net Margins Return on Equity Return on Assets
PyroGenesis Canada-115.14% N/A -60.81%
Genenta Science N/A N/A N/A

Genenta Science has lower revenue, but higher earnings than PyroGenesis Canada.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PyroGenesis Canada$9.14M7.55-$21.12M-$0.04N/A
Genenta ScienceN/AN/A-$7.39MN/AN/A

Summary

Genenta Science beats PyroGenesis Canada on 7 of the 9 factors compared between the two stocks.

How does Genenta Science compare to Greenland Mines Ltd. Common Stock?

Genenta Science (NASDAQ:GNTA) and Greenland Mines Ltd. Common Stock (NASDAQ:GRML) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Genenta Science has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Greenland Mines Ltd. Common Stock has a beta of 7.61, meaning that its stock price is 661% more volatile than the broader market.

In the previous week, Greenland Mines Ltd. Common Stock had 3 more articles in the media than Genenta Science. MarketBeat recorded 5 mentions for Greenland Mines Ltd. Common Stock and 2 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.44 beat Greenland Mines Ltd. Common Stock's score of 0.38 indicating that Genenta Science is being referred to more favorably in the media.

Company Overall Sentiment
Genenta Science Positive
Greenland Mines Ltd. Common Stock Neutral

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 20.1% of Greenland Mines Ltd. Common Stock shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 9.9% of Greenland Mines Ltd. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Greenland Mines Ltd. Common Stock
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Genenta Science's return on equity of 0.00% beat Greenland Mines Ltd. Common Stock's return on equity.

Company Net Margins Return on Equity Return on Assets
Genenta ScienceN/A N/A N/A
Greenland Mines Ltd. Common Stock N/A -137.58%-126.00%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genenta ScienceN/AN/A-$7.39MN/AN/A
Greenland Mines Ltd. Common StockN/AN/A-$10.55M-$0.32N/A

Summary

Genenta Science beats Greenland Mines Ltd. Common Stock on 5 of the 8 factors compared between the two stocks.

How does Genenta Science compare to iBio?

Genenta Science (NASDAQ:GNTA) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Genenta Science has higher earnings, but lower revenue than iBio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genenta ScienceN/AN/A-$7.39MN/AN/A
iBio$400K140.04-$18.38M-$0.58N/A

Genenta Science's return on equity of 0.00% beat iBio's return on equity.

Company Net Margins Return on Equity Return on Assets
Genenta ScienceN/A N/A N/A
iBio N/A -64.97%-54.58%

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 2.8% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Genenta Science has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, iBio has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

iBio has a consensus price target of $4.75, suggesting a potential upside of 206.45%. Given iBio's stronger consensus rating and higher possible upside, analysts clearly believe iBio is more favorable than Genenta Science.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
iBio
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
3 Strong Buy rating(s)
3.17

In the previous week, iBio had 3 more articles in the media than Genenta Science. MarketBeat recorded 5 mentions for iBio and 2 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.44 beat iBio's score of 0.98 indicating that Genenta Science is being referred to more favorably in the media.

Company Overall Sentiment
Genenta Science Positive
iBio Positive

Summary

iBio beats Genenta Science on 7 of the 13 factors compared between the two stocks.

How does Genenta Science compare to MindWalk?

MindWalk (NASDAQ:HYFT) and Genenta Science (NASDAQ:GNTA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

In the previous week, MindWalk and MindWalk both had 2 articles in the media. Genenta Science's average media sentiment score of 1.44 beat MindWalk's score of 0.93 indicating that Genenta Science is being referred to more favorably in the news media.

Company Overall Sentiment
MindWalk Positive
Genenta Science Positive

Genenta Science has lower revenue, but higher earnings than MindWalk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MindWalk$17.59M3.31-$21.69M-$0.20N/A
Genenta ScienceN/AN/A-$7.39MN/AN/A

MindWalk currently has a consensus price target of $5.00, suggesting a potential upside of 296.83%. Given MindWalk's stronger consensus rating and higher probable upside, analysts plainly believe MindWalk is more favorable than Genenta Science.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MindWalk
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 6.8% of MindWalk shares are owned by insiders. Comparatively, 29.0% of Genenta Science shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Genenta Science has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. Genenta Science's return on equity of 0.00% beat MindWalk's return on equity.

Company Net Margins Return on Equity Return on Assets
MindWalk-66.79% -69.37% -39.74%
Genenta Science N/A N/A N/A

MindWalk has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Summary

Genenta Science beats MindWalk on 8 of the 13 factors compared between the two stocks.

Get Genenta Science News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNTA vs. The Competition

Export
MetricGenenta ScienceMED IndustryMedical SectorNASDAQ Exchange
Market Cap$14.46M$3.42B$6.30B$12.20B
Dividend YieldN/A2.29%2.79%5.30%
P/E RatioN/A18.5220.9925.65
Price / SalesN/A301.26555.9878.93
Price / CashN/A122.5142.9455.34
Price / Book0.456.759.706.66
Net Income-$7.39M$24.11M$3.55B$333.63M
7 Day Performance-8.34%-0.53%-0.56%-0.11%
1 Month Performance-8.48%0.34%1.17%3.94%
1 Year Performance-86.31%78.62%41.20%36.07%

Genenta Science Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNTA
Genenta Science
1.3063 of 5 stars		$0.59
-4.3%		N/A-86.8%$14.46MN/AN/A7
IZTC
Invizyne Technologies
N/A$9.89
-0.3%		N/A-23.3%$61.82MN/AN/A29
PYRGF
PyroGenesis Canada
N/A$0.29
-1.7%		N/A+1.1%$60.93M$9.14MN/A90
GRML
Greenland Mines Ltd. Common Stock
0.6029 of 5 stars		$0.50
+0.9%		N/A+226.9%$60.64MN/AN/A5
IBIO
iBio
4.4267 of 5 stars		$1.64
+1.6%		$4.75
+190.5%		N/A$59.09M$400KN/A100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GNTA) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners
The one number Musk can't hide in the S-1
When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...
Behind the Markets | Sponsoredtc pixel
Why I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)
The media's calling it "the biggest IPO in Wall Street history." But I'm not buying it. Institutions got into ...
Decentralized Masters | Sponsoredtc pixel
Read this or regret it forever
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Collect $1,170 a month from silver
I've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...
Investors Alley | Sponsoredtc pixel
The system holding the dollar together is gone…
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel